Eli Lilly and (LLY) Given Hold Rating at Credit Suisse Group

Credit Suisse Group reissued their hold rating on shares of Eli Lilly and (NYSE:LLY) in a report released on Friday, February 2nd. The firm currently has a $80.00 target price on the stock.

LLY has been the topic of several other research reports. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the company a sell rating in a report on Tuesday, October 24th. Barclays increased their target price on Eli Lilly and from $90.00 to $98.00 and gave the company an overweight rating in a report on Friday, October 13th. Berenberg Bank restated a buy rating and issued a $98.00 price objective on shares of Eli Lilly and in a research note on Thursday, October 26th. Zacks Investment Research downgraded shares of Eli Lilly and from a buy rating to a hold rating in a research note on Monday, October 30th. Finally, Leerink Swann upped their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a market perform rating in a research note on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $92.02.

Shares of Eli Lilly and (LLY) opened at $76.23 on Friday. Eli Lilly and has a 12-month low of $73.69 and a 12-month high of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The stock has a market capitalization of $83,936.48, a P/E ratio of -381.13, a price-to-earnings-growth ratio of 1.40 and a beta of 0.23.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The business had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The company’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.95 earnings per share. equities research analysts expect that Eli Lilly and will post 4.88 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a yield of 2.95%. Eli Lilly and’s dividend payout ratio (DPR) is -1,039.95%.

In other news, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now directly owns 4,130 shares of the company’s stock, valued at approximately $334,901.70. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.12, for a total transaction of $780,780.00. Following the transaction, the senior vice president now directly owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 259,610 shares of company stock valued at $22,727,406. 0.20% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Alexandria Capital LLC boosted its holdings in shares of Eli Lilly and by 19,523.2% in the 4th quarter. Alexandria Capital LLC now owns 54,945 shares of the company’s stock valued at $4,641,000 after purchasing an additional 54,665 shares during the last quarter. Suntrust Banks Inc. boosted its holdings in shares of Eli Lilly and by 3.4% in the 4th quarter. Suntrust Banks Inc. now owns 193,928 shares of the company’s stock valued at $16,377,000 after purchasing an additional 6,424 shares during the last quarter. Vantage Financial Partners Ltd. Inc. acquired a new position in shares of Eli Lilly and in the 4th quarter valued at $506,000. Norinchukin Bank The boosted its holdings in shares of Eli Lilly and by 4.3% in the 4th quarter. Norinchukin Bank The now owns 128,415 shares of the company’s stock valued at $10,846,000 after purchasing an additional 5,294 shares during the last quarter. Finally, Ontario Teachers Pension Plan Board boosted its holdings in shares of Eli Lilly and by 6.6% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 47,182 shares of the company’s stock valued at $3,985,000 after purchasing an additional 2,937 shares during the last quarter. Hedge funds and other institutional investors own 76.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2018/02/11/credit-suisse-group-reiterates-hold-rating-for-eli-lilly-and-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply